FDA reviews GSK’s depemokimab for asthma, CRSwNP; decision due Dec. 16

FDA reviews GSK’s depemokimab for asthma, CRSwNP; decision due Dec. 16#FDA #reviews #GSKs #depemokimab #asthma #CRSwNP #decision #due #Dec